Tempus AI, Inc. (NASDAQ:TEM) is a prominent player in the field of AI-driven precision medicine. The company focuses on leveraging artificial intelligence to enhance diagnostic and therapeutic solutions, particularly in oncology. As a leader in this niche, Tempus competes with other tech-driven healthcare companies aiming to revolutionize medical practices through advanced data analytics and AI technologies.
On February 24, 2026, Tempus reported its earnings, revealing an earnings per share (EPS) of -$0.31, which fell short of the estimated EPS of -$0.04. Despite this, the company achieved a revenue of $367.2 million, surpassing the estimated $362.6 million. This revenue marks an 83% increase compared to the previous year, with a 33.5% organic growth excluding contributions from Ambry.
The diagnostics segment was a major contributor, generating $266.9 million in revenue during the fourth quarter, a 121.6% year-over-year growth. This growth was driven by a 29% increase in oncology volume and a 23% rise in hereditary volume. The Data and Applications segment also performed well, adding $100 million, up 25%, while the Insights segment showed a robust 68% growth.
Despite the revenue growth, Tempus faces financial challenges. The company has a negative price-to-earnings (P/E) ratio of -41.21, indicating negative earnings. The enterprise value to operating cash flow ratio is approximately -25.61, highlighting difficulties in generating positive cash flow from operations. The earnings yield is negative at -2.43%, further emphasizing financial difficulties.
Tempus's debt-to-equity ratio is 1.66, indicating a higher level of debt compared to equity. However, the current ratio of 3.13 suggests a strong ability to cover short-term liabilities with short-term assets. Achieving positive adjusted EBITDA for the first time in the previous quarter, with $1.5 million, marks a significant milestone for the company.
